Organization
Division of Urology, IREC, Cliniques Universitaires Saint Luc, UCLouvain, Brussels, Belgium
1 abstract
Abstract
Efficacy and safety of darolutamide in Chinese patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subpopulation analysis of the phase 3 ARASENS study.Org: Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, Division of Urology, IREC, Cliniques Universitaires Saint Luc, UCLouvain, Brussels, Belgium, Northwestern University, Feinberg School of Medicine, Chicago, IL, Bayer Healthcare Company Ltd., Beijing, China, Bayer Healthcare Co Ltd, Beijing, China,